Falkson Samuel R, Zhang Karen, Bhambhvani Hriday P, Wild Jennifer L, Griffin Ann, Kelley Robin K, Gephart Melanie Hayden
Department of Neurosurgery, Stanford University Medical Center, Stanford, CA, USA.
UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
J Gastrointest Oncol. 2022 Apr;13(2):822-832. doi: 10.21037/jgo-21-818.
Biliary cancers are rare, and few reported cases of brain metastases from primary biliary cancers exist, especially describing patients in the United States. This report assesses the proportion and incidence of brain metastases arising from primary biliary cancers [cholangiocarcinoma (CCA) and gallbladder cancer] at Stanford University and the University of California, San Francisco, describes clinical characteristics, and provides a case series.
We queried 3 clinical databases at Stanford and the University of California, San Francisco to retrospectively identify and review the charts of 15 patients with brain metastases from primary biliary cancers occurring between 1990 to 2020.
Among patients with brain metastases analyzed at Stanford (3,585), 6 had a primary biliary cancer, representing 0.17% of all brain metastases. Among biliary cancer patients at the University of California, San Francisco (1,055), 9 had brain metastases, representing an incidence in biliary cancer of 0.85%. A total of 15 biliary cancer patients with brain metastases were identified at the two institutions. Thirteen out of 15 patients (86.7%, 95% CI: 59.5-98.3) were female. The median overall survival from primary biliary cancer diagnosis was 214 days (95% CI: 71.69-336.82 days) and subsequent OS from the time of brain metastasis diagnosis was 57 days (95% CI: 13.43-120.64 days). Death within 90 days of brain metastasis diagnosis occurred in 66.67% of patients (95% CI: 38.38-88.17).
Brain metastases from primary biliary cancers are rare, with limited survival once diagnosed. This report can aid health care providers in caring for patients with brain metastases from primary biliary cancers.
胆管癌较为罕见,原发性胆管癌发生脑转移的报道病例很少,尤其是关于美国患者的描述。本报告评估了斯坦福大学和加利福尼亚大学旧金山分校原发性胆管癌(胆管癌和胆囊癌)发生脑转移的比例和发病率,描述了临床特征,并提供了一个病例系列。
我们查询了斯坦福大学和加利福尼亚大学旧金山分校的3个临床数据库,以回顾性地识别和审查1990年至2020年间发生原发性胆管癌脑转移的15例患者的病历。
在斯坦福大学分析的脑转移患者中(3585例),6例患有原发性胆管癌,占所有脑转移患者的0.17%。在加利福尼亚大学旧金山分校的胆管癌患者中(1055例),9例发生脑转移,在胆管癌中的发病率为0.85%。两所机构共识别出15例原发性胆管癌脑转移患者。15例患者中有13例(86.7%,95%CI:59.5-98.3)为女性。原发性胆管癌诊断后的中位总生存期为214天(95%CI:71.69-336.82天),脑转移诊断后的后续总生存期为57天(95%CI:13.43-120.64天)。66.67%的患者在脑转移诊断后90天内死亡(95%CI:38.38-88.17)。
原发性胆管癌脑转移罕见,一旦诊断,生存期有限。本报告可为医疗保健提供者护理原发性胆管癌脑转移患者提供帮助。